Insulin Lispro (Humalog) Injectable Suppliers & Bulk Manufacturers

Available Forms: Vials/pens

Available Strengths: U-100, U-200

Reference Brands: Humalog, Admelog, Fiasp(US); Humalog, Fiasp(EU)

Category: Diabetes

Insulin Lispro (Humalog) is a rapid-acting insulin that quickly mimics natural insulin release post-meal. It lowers blood sugar rapidly, providing flexible dosing around mealtimes. Benefits include quick onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy, essential for effective management of diabetes. Insulin Lispro (Humalog) injectable is available in Vials/pens and strengths such as U-100, U-200. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Insulin Lispro (Humalog) injectable is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Insulin Lispro (Humalog) injectable can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Insulin Lispro (Humalog) is a rapid-acting insulin approved in the EU and US for post-meal blood glucose control. In the EU, Novo Nordisk’s Fiasp, a faster-acting version, is regulated by EMA with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, the FDA has approved Humalog and biosimilars like Admelog based on comprehensive clinical data, biosimilarity, and ongoing pharmacovigilance. Both regions require detailed regulatory dossiers for approval and post-marketing safety monitoring. For expert assistance with pharmaceutical dossiers and compliance, visit PharmaTradz, your trusted partner in regulatory solutions.